Back to Search Results
Image Place holder

Sepideh Mehravaran, MD

 
Specialty: Pathology
Program: Pathology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Dr. Mehravaran received her MD degree at Iran University of Medical Sciences – School of Medicine, Tehran. She completed a one-year (PGY-1) Anatomic and Clinical Pathology Residency at Vidant Medical Center, East Carolina University, in Greeneville, North Carolina and went on to finish her Anatomic and Clinical Pathology Residency at Baylor College of Medicine in Houston, Texas. Dr. Mehravaran completed a Breast Pathology Fellowship at Baylor College of Medicine. She joins us from McMaster University, Juravinski Hospital, Hamilton, Ontario, where she was an Assistant Professor in the Department of Anatomic Pathology. Dr. Mehravaran’s clinical focus is breast pathology, especially invasive ductal carcinoma and fibroepithelial lesions. Her research focuses on identifying and studying breast cancer biomarkers for diagnostic, prognostic, predictive, and targeted therapy purposes.


Education & Training

Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Kulkarni AM, Mehravaran S, Lee SY. IOTA Simple Rules: Review of 10 Points for Evaluation of Adnexal Masses. Radiographics. 2022 Jan.42(1):E29-E30. Pubmedid: 34990323.
  • Bhavsar-Bhakta P, Hamza M, Mehravaran S, Krishnan B, He Q, Tyring S, Rady P, Rivero G, Cohen DN, Sosa IR. The contribution of human papilloma virus infection to cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. EJHaem. 2021 May.2(2):228-235. Pubmedid: 35845291. Pmcid: PMC9176019.
  • Veeraraghavan J, Gutierrez C, Sethunath V, Mehravaran S, Giuliano M, Shea MJ, Mitchell T, Wang T, Nanda S, Pereira R, Davis R, Goutsouliak K, Qin L, De Angelis C, Diala I, Lalani AS, Nagi C, Hilsenbeck SG, Rimawi MF, Osborne CK, Schiff R. Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. NPJ Breast Cancer. 2021 May.7(1):63. Pubmedid: 34045483. Pmcid: PMC8159999.
  • Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, Gutierrez C, Chamness GC, Feng Q, O'Malley BW, Selenica P, Weigelt B, Reis-Filho JS, Cohen O, Wagle N, Nardone A, Jeselsohn R, Brown M, Rimawi MF, Osborne CK, Schiff R. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proc Natl Acad Sci U S A. 2019 Dec.116(52):26823-26834. Pubmedid: 31826955. Pmcid: PMC6936436.
  • Ensani F, Mehravaran S, Irvanlou G, Aghaipoor M, Vaeli S, Hajati E, Khorgami Z, Nasiri S. Fine-needle aspiration cytology and flow cytometric immunophenotyping in diagnosis and classification of non-Hodgkin lymphoma in comparison to histopathology. Diagn Cytopathol. 2012 Apr.40(4):305-310. Pubmedid: 22431318.
  • Eskandary H, Basiri M, Nematollahi-Mahani SN, Mehravaran S. The role of stem cells in tumor targeting and growth suppression of gliomas. Biologics. 2011 Jul.5:61-70. Pubmedid: 21637731. Pmcid: PMC3104605.

Patient Comments
Overall Satisfaction
0
★★★★★
★★★★★

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments